Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financi...(to the following items that Endo has exc...),Health

Date:2/27/2009

to the following items that Endo has excluded in prior periods, as applicable, the impact of any of the non-recurring costs of future business combinations, estimated upfront and milestone payments to partners, certain contract termination costs, the payment of certain separation benefits, asset impairment charges, changes in the fair value of certain of our financial instruments and changes in the fair value of certain business combination contingent liabilities.

Note to Investors

Endo will conduct a conference call with financial analysts to discuss this news release today at 10:30 a.m. ET. Investors and other interested parties may access the conference call by dialing (866) 543-6405 (domestic) or (617) 213-8897 (international). Please dial in 10 minutes prior to the scheduled start time and reference passcode 10990222.

A replay of the call will be available from February 27 at 1:30 p.m. ET by dialing (888) 286-8010 (domestic) or (617) 801-6888 (international), passcode 15067182, and will run until 12:00 a.m. ET on March 6, 2009. A simultaneous webcast of the call for interested investors and others may be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until 12:00 a.m. ET on March 6, 2009. The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.

Supplemental Financial Information

The following tables provide a reconciliation of our GAAP statements of operations to our adjusted statements of operations for each of the three months ended December 31, 2008 and December 31, 2007 (Certain prior period amounts have been reclassified to conform to the current period presentation) (in thousands, except per share data):

    Three Months Ended December 31,    Actual
     2008 (unaudited)                  (GAAP)       Adjustment
'/>"/>
SOURCE  Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Related medicine news :

1. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
2. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
3. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
4. Endo Pharmaceuticals Appoints William Montague to Board of Directors
5. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
6. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
7. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
8. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
9. Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
10. Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
11. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results